We help Atlantic Canada companies, industries and researchers use genomic insights and innovations to solve real-world problems.


Working with a broad array of partners — companies, researchers, universities, hospitals, health centres, clinicians, research institutions, industry associations, not for profits, public sector departments and agencies — we aim to turn problems and challenges into solutions and opportunities through applied genomics and other ‘omics research and development.

Steve Armstrong, PhD
President & CEO
Genome Atlantic

Impacts At A Glance:

Nova Scotia

Salmon aquaculture has been a catalyst for reviving Nova Scotia’s rural and coastal communities, creating hundreds of jobs and adding many millions of dollars in value to the provincial economy.  Supporting this vital industry is important to Genome Atlantic and over the years we have aligned with local industry, government and researchers to address many of the industry’s challenges while improving its sustainability.

This month the Government of Canada announced research support for yet another Genome Atlantic aquaculture initiative – a $4.7 Million Complex Gill Health Initiative that will focus on Complex Gill Disease (CGD), a growing health challenge for salmon farming operations in both the Pacific and North Atlantic.  This project, co-led by Genome Atlantic and Genome BC, will validate biomarkers of healthy and compromised gills of Atlantic salmon and use these to develop an early warning system for the development of gill disease on Atlantic salmon production sites across Canada. The resulting genomics-enabled tools for fish health will guide the management and intervention strategies for complex gill disease in Atlantic salmon.

We congratulate the coast-to-coast research team and acknowledge the generous support of project funders the Government of Canada through Genome Canada, the federal Department of Fisheries and Oceans, Genome BC, BC Salmon Farmers Association, Mitacs Canada, Memorial University, the University of Prince Edward Island, and industry partners Cermaq Canada, Grieg Seafood, and Cargill.

In February, Nova Scotia’s Forestry Innovation Transition Trust provided funding to Genome Atlantic of $315,500 over four years to support The Atlantic Tree Improvement Council (AtlanTIC) in producing more resilient, commercially important tree species in Nova Scotia. The funding will help to support collaborative breeding, field testing and new tree improvement technologies such as genomics which have been shown to shorten breeding cycles and increase growth rate, wood quality, pest resistance and adaptation to climate change.

Adding genomics to the tree improvement toolkit can save considerable time and money for the forestry industry. For example, a recent genomics project that Genome Atlantic carried out in collaboration with a regional industry partner resulted in an estimated 10% increase in production of commercial spruce trees on a test tract of land where the project was conducted. The AtlanTIC collaborative will be a means for conducting more proof of concept applications of tree improvement technologies, and sharing the results with companies across the region.

Genome Atlantic is pleased to partner with AtlanTIC to help the forestry industry realize the economic and environmental benefits of tree improvement technologies, and we thank the Forestry Innovation Transition Trust for their generous support!

The Chief Medical Officer of Canada has consistently highlighted the critical importance of COVID-19 testing capacity to support re-opening the economy, and genomic tools are proving to be invaluable in this regard. Genomics plays a vital role in detecting infections, tracking disease spread, and developing tests, vaccines and treatments. Genome Atlantic is working tirelessly to support local research focusing on some of our biggest challenges in relation to the pandemic.

On June 15, we announced more than $300,000 in funding for two research projects led by Dalhousie University scientists – one focusing on biomarkers to predict disease severity, and the other piloting a simple, quick and inexpensive surveillance tool for screening COVID-19 in high-risk settings like long-term care facilities fish processing and meat packing plants, fishing boats, etc. Both projects are supported by Genome Atlantic with $250,000 in funding from Genome Canada’s COVID-19 Regional Genomics Initiative and an additional $60,000 from Research Nova Scotia to the surveillance project. (Research Nova Scotia provided support to the biomarkers research earlier this year.)

Pooling together our data about COVID-19 is one of the best, most effective ways that Canada can respond to current and future pandemics. The recent announcement of a $40 Million Canadian COVID Genomics Network (CanCOGeN) is great news. CanCOGeN will undertake two related genomics projects to help us understand how the virus works, how it is evolving, and why people experience such different health outcomes. CanCOGeN will sequence the complete genomes of up to 10,000 patients and up to 150,000 viral samples and will build a bank of “virus to patient” data that will inform decision-making by public health authorities and support the development of therapies and vaccines. Of critical importance, CanCOGeN will establish and manage a framework of cross-Canada safe data sharing, coordination and analysis. CanCOGeN is led by Genome Canada in partnership with the six regional Genome Centres including Genome Atlantic, as well as national and provincial public health labs, genome sequencing centres, hospitals and universities.  (In Nova Scotia, Genome Atlantic is working with the Nova Scotia Health Authority.)

There are many pieces to the COVID-19 puzzle and genomics is helping us find the answers.  But how exactly? Genome Atlantic developed two short animated videos to explain. (Scroll down the web page to Special Feature: Genomics in the battle against COVID-19.) Video #1, On the Trail of Covid-19, is about detecting infections and understanding how the virus mutates while the second video, The Race for a Vaccine, focuses on tracking mutations and developing vaccines and treatments. Please take a few minutes to watch them.  These videos are intended to provide a deeper understanding of how the scientific community has responded while conveying well-founded hope.

All Genome Atlantic projects are end-user-driven and aimed at finding solutions to some of the biggest challenges facing Atlantic Canada’s economy, now and in the future. The practical application and advantages of genomic solutions is reflected in private sector investment in Genome Atlantic projects. In the company-led portion of our portfolio, private sector investment has grown from 8% in 2008 to more than 25% currently, a testament to how keen Nova Scotian and Atlantic Canadian businesses are to invest in genomics.

More Related News and Updates

Sign up for our free newsletter.

We will deliver SEQUENCE to your inbox. SEQUENCE highlights the latest genomics applications and research initiatives in Atlantic Canada. Subscribe to stay informed.

Read recent issues here.

Sign up for our free newsletter.

We will deliver SEQUENCE to your inbox. SEQUENCE highlights the latest genomics applications and research initiatives in Atlantic Canada. Subscribe to stay informed.

Read recent issues here.

What Our Clients Say?

“Access to genomic technology and the opportunity to work with genome Atlantic are crucial to the success of our program which has long term implication for both our company and the developing oyster industry.”

Dr. André Mallet

President, L’Étang Ruisseau Bar Ltd., Shippagan, N.B.

We benefit from the stimulus and interest that Genome Atlantic provides… what they bring is indispensible.

Dr. Mark Skinner

Marine Ecology Technical Leader for Canada, Stantec